The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

Imatinib was the first signal transduction inhibitor (STI), used in a clinical setting. It prevents a
BCR-ABL protein from exerting its role in the oncogenic pathway in chronic myeloid …

Summary Abstract Imatinib (Gleevec®, Glivec®) is a synthetic tyrosine kinase inhibitor used
in the treatment of chronic myeloid leukaemia (CML). It is specifically designed to inhibit the …

Imatinib mesylate is considered standard of care for first-line treatment of chronic phase
chronic myeloid leukemia (CML-CP). In the phase III, randomized, open-label International …

For almost 10 years imatinib has been the therapeutic standard of chronic myeloid leukemia.
The introduction of other tyrosine kinase inhibitors (TKIs) raised a debate on treatment …

Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with
imatinib (IM) at 400 mg/day (n= 400) could be optimized by doubling the dose (n= 420) …

The introduction of imatinib, a specific inhibitor of the Bcr-Abl tyrosine kinase, has
dramatically changed the management of chronic myeloid leukemia (CML). More than …

Treatment options for chronic myeloid leukemia (CML) have changed dramatically during
the last decades. Interferon-α treatment and stem cell transplantation (SCT) clearly improved …

Imatinib mesylate (STI571, Gleevec, Glivec; Novartis, Basel, Switzerland) has profoundly
changed the management of chronic myeloid leukemia (CML). The unprecedented efficacy …

Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …